RxDoctor Payments Data

Alejandra Vazquez-Bojorquez

Family Medicine · Chula Vista, CANPI 1447817671

Payments from drug & device makers

$2,008in general payments, 2019–2025

Across 69 payments — averaging $29.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$345
  • Lilly USA, LLC$241
  • Exact Sciences$195
  • GSK$171
  • Edwards Lifesciences$150
  • Pfizer$144
  • plus $764 from 13 others

What the payments were for

  • Food & beverage$2,008100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,008 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$21,096
Medicare patients
53
Services billed
240

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban50$53,885
TrulicityDulaglutide36$42,185
JanuviaSitagliptin Phosphate27$35,397
JardianceEmpagliflozin39$34,204
OzempicSemaglutide28$27,158
MounjaroTirzepatide22$23,553
RybelsusSemaglutide18$20,977
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$16,496
FarxigaDapagliflozin Propanediol13$16,151
EntrestoSacubitril/Valsartan16$13,202
Atorvastatin Calcium365$5,394
Lantus SolostarInsulin Glargine,hum.Rec.Anlog40$5,133
Losartan Potassium178$2,273
Levothyroxine Sodium138$2,137
Gabapentin84$1,691

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$241$65,73758 claims
PfizerEliquis$144$53,88550 claims
Boehringer IngelheimJardiance$48$34,20439 claims
GSKTrelegy Ellipta$171$16,49618 claims
AstraZenecaFarxiga$345$16,15113 claims
NovartisEntresto$17$13,20216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Chula Vista

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →